Status:
COMPLETED
PTRG-DES Consortium
Lead Sponsor:
Gyeongsang National University Hospital
Collaborating Sponsors:
Korean Society of Interventional Cardiology
Conditions:
Coronary Artery Disease
Clopidogrel, Poor Metabolism of
Eligibility:
All Genders
18+ years
Brief Summary
The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 pa...
Detailed Description
The investigators enrolled patients treated with DES during DAPT including clopidogrel who had at least one of VerifyNow test (PRU and ARU) and genotyping. In this consortium, the investigators tried ...
Eligibility Criteria
Inclusion
- Consecutive patients at every centre successfully treated with one or more DES approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were eligible for enrolment, regardless of patient or lesion complexity.
Exclusion
- the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI.
- Any P2Y12 inhibitor other than clopidogrel
- PCI strategy other than DES
- Needed oral anticoagulant (e.g. atrial fibrillation)
Key Trial Info
Start Date :
July 9 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
13160 Patients enrolled
Trial Details
Trial ID
NCT04734028
Start Date
July 9 2003
End Date
June 30 2020
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gyeongsang National University Changwon Hospital
Changwon, Gyeongsangnam-do, South Korea, 51472